Logo image of ROIV

ROIVANT SCIENCES LTD (ROIV) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ROIV - BMG762791017 - Common Stock

20.43 USD
-0.56 (-2.67%)
Last: 12/9/2025, 4:30:01 PM
20.3999 USD
-0.03 (-0.15%)
After Hours: 12/9/2025, 4:30:01 PM
Fundamental Rating

4

ROIV gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 531 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ROIV as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, ROIV is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ROIV has reported negative net income.
ROIV had a negative operating cash flow in the past year.
In the past 5 years ROIV reported 4 times negative net income.
In the past 5 years ROIV always reported negative operating cash flow.
ROIV Yearly Net Income VS EBIT VS OCF VS FCFROIV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 0 1B -1B 2B 3B 4B

1.2 Ratios

With an excellent Return On Assets value of -7.39%, ROIV belongs to the best of the industry, outperforming 85.12% of the companies in the same industry.
ROIV's Return On Equity of -8.57% is amongst the best of the industry. ROIV outperforms 88.14% of its industry peers.
Industry RankSector Rank
ROA -7.39%
ROE -8.57%
ROIC N/A
ROA(3y)4.94%
ROA(5y)-9.82%
ROE(3y)-5.99%
ROE(5y)-22.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROIV Yearly ROA, ROE, ROICROIV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 50 -50

1.3 Margins

ROIV has a better Gross Margin (96.41%) than 96.23% of its industry peers.
In the last couple of years the Gross Margin of ROIV has remained more or less at the same level.
ROIV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.96%
GM growth 5Y-0.3%
ROIV Yearly Profit, Operating, Gross MarginsROIV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 5K 10K

More info and screens

9

2. Health

2.1 Basic Checks

ROIV does not have a ROIC to compare to the WACC, probably because it is not profitable.
ROIV has less shares outstanding than it did 1 year ago.
The number of shares outstanding for ROIV has been increased compared to 5 years ago.
ROIV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ROIV Yearly Shares OutstandingROIV Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
ROIV Yearly Total Debt VS Total AssetsROIV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 2B 4B 6B

2.2 Solvency

ROIV has an Altman-Z score of 12.68. This indicates that ROIV is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ROIV (12.68) is better than 84.37% of its industry peers.
There is no outstanding debt for ROIV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.68
ROIC/WACCN/A
WACC9.22%
ROIV Yearly LT Debt VS Equity VS FCFROIV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 2B 4B

2.3 Liquidity

ROIV has a Current Ratio of 33.70. This indicates that ROIV is financially healthy and has no problem in meeting its short term obligations.
ROIV's Current ratio of 33.70 is amongst the best of the industry. ROIV outperforms 98.49% of its industry peers.
ROIV has a Quick Ratio of 33.70. This indicates that ROIV is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 33.70, ROIV belongs to the top of the industry, outperforming 98.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 33.7
Quick Ratio 33.7
ROIV Yearly Current Assets VS Current LiabilitesROIV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 2B 4B 6B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.65% over the past year.
Looking at the last year, ROIV shows a very negative growth in Revenue. The Revenue has decreased by -74.11% in the last year.
Measured over the past years, ROIV shows a very negative growth in Revenue. The Revenue has been decreasing by -15.56% on average per year.
EPS 1Y (TTM)17.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.16%
Revenue 1Y (TTM)-74.11%
Revenue growth 3Y-19.3%
Revenue growth 5Y-15.56%
Sales Q2Q%-64.89%

3.2 Future

Based on estimates for the next years, ROIV will show a very strong growth in Earnings Per Share. The EPS will grow by 52.70% on average per year.
Based on estimates for the next years, ROIV will show a very strong growth in Revenue. The Revenue will grow by 108.81% on average per year.
EPS Next Y-407.96%
EPS Next 2Y-142.4%
EPS Next 3Y-59.74%
EPS Next 5Y52.71%
Revenue Next Year-78.75%
Revenue Next 2Y0.68%
Revenue Next 3Y104.33%
Revenue Next 5Y108.81%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ROIV Yearly Revenue VS EstimatesROIV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B
ROIV Yearly EPS VS EstimatesROIV Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ROIV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ROIV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ROIV Price Earnings VS Forward Price EarningsROIV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ROIV Per share dataROIV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

A cheap valuation may be justified as ROIV's earnings are expected to decrease with -59.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-142.4%
EPS Next 3Y-59.74%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ROIV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ROIVANT SCIENCES LTD

NASDAQ:ROIV (12/9/2025, 4:30:01 PM)

After market: 20.3999 -0.03 (-0.15%)

20.43

-0.56 (-2.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)N/A N/A
Inst Owners64.96%
Inst Owner ChangeN/A
Ins Owners3.84%
Ins Owner Change4.51%
Market Cap14.21B
Revenue(TTM)20.33M
Net Income(TTM)-373.97M
Analysts85.56
Price Target24.76 (21.19%)
Short Float %5.05%
Short Ratio2.9
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)22.89%
Min EPS beat(2)-4.36%
Max EPS beat(2)50.15%
EPS beat(4)3
Avg EPS beat(4)58.4%
Min EPS beat(4)-4.36%
Max EPS beat(4)180.12%
EPS beat(8)6
Avg EPS beat(8)50.87%
EPS beat(12)7
Avg EPS beat(12)31.34%
EPS beat(16)9
Avg EPS beat(16)18.02%
Revenue beat(2)0
Avg Revenue beat(2)-74.21%
Min Revenue beat(2)-77.83%
Max Revenue beat(2)-70.59%
Revenue beat(4)0
Avg Revenue beat(4)-64.48%
Min Revenue beat(4)-86.28%
Max Revenue beat(4)-23.24%
Revenue beat(8)2
Avg Revenue beat(8)-34.24%
Revenue beat(12)5
Avg Revenue beat(12)-18.03%
Revenue beat(16)7
Avg Revenue beat(16)-4.01%
PT rev (1m)23.53%
PT rev (3m)24.48%
EPS NQ rev (1m)10.44%
EPS NQ rev (3m)4.6%
EPS NY rev (1m)12.68%
EPS NY rev (3m)10.32%
Revenue NQ rev (1m)-9.25%
Revenue NQ rev (3m)-9.25%
Revenue NY rev (1m)-13.28%
Revenue NY rev (3m)-20.57%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 698.95
P/FCF N/A
P/OCF N/A
P/B 3.26
P/tB 3.26
EV/EBITDA N/A
EPS(TTM)-0.56
EYN/A
EPS(NY)-1.47
Fwd EYN/A
FCF(TTM)-1.13
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS0.03
BVpS6.27
TBVpS6.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.39%
ROE -8.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.41%
FCFM N/A
ROA(3y)4.94%
ROA(5y)-9.82%
ROE(3y)-5.99%
ROE(5y)-22.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.96%
GM growth 5Y-0.3%
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 228.14%
Cap/Sales 71.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 33.7
Quick Ratio 33.7
Altman-Z 12.68
F-Score4
WACC9.22%
ROIC/WACCN/A
Cap/Depr(3y)35.38%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.59%
Cap/Sales(5y)19.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.16%
EPS Next Y-407.96%
EPS Next 2Y-142.4%
EPS Next 3Y-59.74%
EPS Next 5Y52.71%
Revenue 1Y (TTM)-74.11%
Revenue growth 3Y-19.3%
Revenue growth 5Y-15.56%
Sales Q2Q%-64.89%
Revenue Next Year-78.75%
Revenue Next 2Y0.68%
Revenue Next 3Y104.33%
Revenue Next 5Y108.81%
EBIT growth 1Y-3.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-16.43%
EBIT Next 3Y-1.08%
EBIT Next 5YN/A
FCF growth 1Y7.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.22%
OCF growth 3YN/A
OCF growth 5YN/A

ROIVANT SCIENCES LTD / ROIV FAQ

What is the ChartMill fundamental rating of ROIVANT SCIENCES LTD (ROIV) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ROIV.


What is the valuation status of ROIVANT SCIENCES LTD (ROIV) stock?

ChartMill assigns a valuation rating of 0 / 10 to ROIVANT SCIENCES LTD (ROIV). This can be considered as Overvalued.


How profitable is ROIVANT SCIENCES LTD (ROIV) stock?

ROIVANT SCIENCES LTD (ROIV) has a profitability rating of 3 / 10.


What is the expected EPS growth for ROIVANT SCIENCES LTD (ROIV) stock?

The Earnings per Share (EPS) of ROIVANT SCIENCES LTD (ROIV) is expected to decline by -407.96% in the next year.